151 related articles for article (PubMed ID: 34686780)
1. Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
Öcal O; Ingrisch M; Ümütlü MR; Peynircioglu B; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Iezzi R; Benito A; Pech M; Malfertheiner P; Ricke J; Seidensticker M
Br J Cancer; 2022 Feb; 126(2):211-218. PubMed ID: 34686780
[TBL] [Abstract][Full Text] [Related]
2. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
3. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Öcal O; Rössler D; Gasbarrini A; Berg T; Klümpen HJ; Bargellini I; Peynircioglu B; van Delden O; Schulz C; Schütte K; Iezzi R; Pech M; Malfertheiner P; Sangro B; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2487-2496. PubMed ID: 34541612
[TBL] [Abstract][Full Text] [Related]
4. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
5. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
6. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
7. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma.
Öcal O; Schütte K; Malfertheiner P; Berg T; Loewe C; Klümpen HJ; Zech CJ; van Delden O; Ümütlü MR; Deniz S; Khaled NB; De Toni EN; Hoang TPT; Seidensticker R; Aghdassi A; Pech M; Ricke J; Seidensticker M
Eur J Radiol; 2023 Nov; 168():111120. PubMed ID: 37806190
[TBL] [Abstract][Full Text] [Related]
9. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
[TBL] [Abstract][Full Text] [Related]
10. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O; Schinner R; Schütte K; de Toni EN; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Gasbarrini A; Sangro B; Pech M; Malfertheiner P; Ricke J; Seidensticker M;
Cancer Imaging; 2022 Jan; 22(1):1. PubMed ID: 34983668
[TBL] [Abstract][Full Text] [Related]
11. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
12. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
13. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
[TBL] [Abstract][Full Text] [Related]
14. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
[TBL] [Abstract][Full Text] [Related]
15. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Fidan E; Fidan S; Merev E; Kazaz N
Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
[TBL] [Abstract][Full Text] [Related]
16. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
17. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
[TBL] [Abstract][Full Text] [Related]
18. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma.
Kostek O; Yilmaz E; Bekir Hacıoglu M; Erdogan B; Kodaz H; Turkmen Bekmez E; Hacibekiroglu I; Uzunoglu S; Tuncbilek N; Cicin I
J BUON; 2018; 23(4):979-984. PubMed ID: 30358202
[TBL] [Abstract][Full Text] [Related]
19. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
[TBL] [Abstract][Full Text] [Related]
20. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation.
Huang K; Dong Z; Cai H; Huang M; Peng Z; Xu L; Jia Y; Song C; Li ZP; Feng ST
BMC Cancer; 2019 Apr; 19(1):364. PubMed ID: 30999947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
